Thirty B-cell chronic lymphocytic leukemia patients were treated with fludarabine-cyclophosphamide-rituximab (FCR) and immune cell counts (natural killer (NK) cells, CD4, CD8, Tcd and monocytes) were monitored from the end of treatment (EOT) up to 36 months (M36). Moreover, nonleukemic peripheral blood lymphocyte cytotoxicity (PBL/CTC) as well as rituximab (RTX)-dependent PBL/CTC was also measured at the initiation of therapy, EOT and M12. These parameters were correlated with post-FCR monitoring of the minimal residual disease (MRD) level in blood using a four-color flow cytometry technique. FCR induced a profound and sustained depletion of all T-cell populations, Tcd being the most affected, whereas NK cells were relatively preserved. Both basal and interleukin-2-stimulated nonleukemic PBL/CTC against MEC-2, a CLL cell line, increased during the post-FCR period. There was no correlation between immune recovery parameters and MRD progression profile, except that patients with high post-FCR CD4 þ counts experienced rapid MRD progression. MRD at M12 predicts clinical relapse. The limited data show RTX-mediated LBL/CTC activity against autologous B-cell cells in individuals with o1% residual disease at M12, opening avenues for immunomodulation post-FCR with anti-CD20 antibodies. To conclude, our study suggests that MRD increase at M12 precedes disease evolution post-FCR, and should be assessed as a surrogate marker for proactive management of CLL relapse.
Introduction
Recent therapeutic successes in B-cell chronic lymphocytic leukemia (B-CLL) management were achieved by combinations of purine analogs, alkylating agents and monoclonal antibodies. 1 In this regard, the fludarabine, cyclophosphamide, rituximab (FCR) schedule is now generally considered as one of the best first-line regimens, yielding a 95% overall response rate and 52% complete response (CR). Moreover, FCR induces a molecular response rate as high as 66%. 2 However, FCR therapy results in a profound immunosuppression, mainly due to neutropenia during the treatment, but also related to severe and sustained B-and T-cell depletion over the 2-year posttreatment period. FCR-mediated immunosuppression is reflected by a significant rate of opportunistic infections, which occur during the post-treatment period. 1 It has also been proposed that immunosuppression could also contribute to the emergence of second malignancies, including leukemia and Richter's syndrome, which has been observed in the setting of both B-CLL and Waldenströ m's disease. [3] [4] [5] Whether FCR therapy could affect some specific immune cell population and natural effector cell function is unknown. This question is still of interest based on two considerations. First, it is conceivable that host immune function may contribute to the control of the disease; for example, B-CLL relapse reflects escape to innate immunity through proper deficit in natural killer (NK) or Tgd cell function, which can be further worsened by treatment. [6] [7] [8] Second, in the perspective of maintenance therapy with monoclonal antibodies, 9 including rituximab (RTX), it is important to know whether antibody-dependent cellular cytotoxicity (ADCC) capacity of natural effector cells is preserved during the post-FCR period. For this reason, we have measured at different times immune cell counts (NK, CD4, CD8, Tgd), in vitro nonleukemic peripheral blood lymphocyte (PBL) cytotoxicity with or without interleukin (IL)-2, reflecting NK and lymphokine activated killer (LAK) function, respectively, as well as RTX-dependent PBL ADCC against autologous leukemic cells. Finally, these values were correlated with post-FCR monitoring of the minimal residual disease (MRD) level in blood used in this study as a parameter of disease control.
Patients and methods

Patients and treatment
From December 2005 to December 2008, 30 patients with B-CLL referred to our University Hospital who received FCR as their frontline treatment were prospectively evaluated on informed consent (according to the local ethics board recommendations). Treatment initiation was based on the National Cancer Institute-International Workshop on Chronic Lymphocytic Leukemia (NCI-IWCLL) criteria, and associated fludarabine (40 mg/m 2 at days 1-3, per os), cyclophosphamide (250 mg/m 2 at days 1-3, per os) and RTX (375 mg/m 2 at day 1 for course 1, and then 500 mg/m 2 at day 1 for courses 2-6, intravenously). Response was assessed 3 months after the last FCR course, and patients were classified according to the NCI-IWCLL criteria, except for bone marrow biopsy (patients with clinical and biological evidence of CR are therefore considered as CR or nodular PR patients). Bone marrow cytological and phenotypical studies were only provided to PR patients, to stratify them as CRi (incomplete bone marrow recovery) or PRd (disease related), as described elsewhere.
1,10
Immunological studies At different times following treatment completion (end of treatment, EOT), fresh whole blood was used for immune cell counts and immunophenotype profile. PBLs were stained with two combinations of monoclonal antibodies: CD3-FITC/CD8-PE/CD45-PerCP/CD4-APC in trucount tubes and TCRVg9d2-FITC/CD56-PE/CD3-PerCP-Cy5.5/CD16PE-Cy7/CD45-APC-H7, purchased from BD Biosciences (Becton-Dickinson France SAS, Le Pont de Claix, France), gated on CD45/SS, and acquired on a FACSCANTO II BD. The lymphocyte absolute counts were obtained directly with the CANTO software on the trucount tube. Monoclonal antibodies were purchased from BD Biosciences. 11, 12 All MRD data were obtained from fresh blood samples using a FACSCalibur BD. Acquisition was stopped when all leukocytes in samples had been processed (a median of 115 000 events were analyzed). The sensitivity of this assay is one CLL cell among 10 4 leukocytes. These combinations allowed a distinct determination of B-CLL and normal B cells.
MRD flow cytometry
Cell-and antibody-mediated cellular cytotoxicity
The natural cytotoxicity and ADCC function of effector cells from CLL patients were tested using the classical chromium release assay. Briefly, PBL from CLL patients were stimulated or not with recombinant glycosylated IL-2 (10 ng/ml, a kind gift from Sanofi-Aventis, Toulouse, France) during 3 days in RPMI 10% fetal calf serum at 37 1C, 5% CO2 and used as effector cells. Target cells (MEC-2 or B cells from autologous patients, and frozen before treatment) were incubated in RPMI 1% fetal calf serum for 1 h at 37 1C with 51 Cr (Sodium Chromate, Perkin Elmer, Courtaboeuf, France) (100 mCi for 10 6 cells). Cells were then washed and incubated or not with RTX (10 mg/ml) for 15 min at room temperature. Cells were washed again and plated at 10 4 cells per well in round-bottom 96-well plates. Increasing amounts of effector cells were added to triplicate wells as an NK/target ratio ranging from 0.1:1 to 2:1 depending on the patients. This ratio was calculated from the NK percentage obtained by flow cytometric analysis. Control wells contained only target cells (pre-coated or not with RTX) to measure spontaneous release or target cells with 0.1% Triton X-100 to measure maximal release. After centrifugation, plates were incubated for 4 h at 37 1C with 5% CO2. Then 50 ml were collected from each well and counted in a gamma counter. The percentage of specific lysis was calculated as follows: ((sample release-spontaneous release)/(maximal release-spontaneous release)) Â 100.
Statistical methods
Student's t-test was used for comparison of independent samples, and Mann-Whitney U-test for comparison of nonparametric variables. All statistical tests were two-sided and used a P-value of 0.05 for statistical significance. Survival data were carried out using Statistica software (Statsoft, Tulsa, OK, USA) according to the Kaplan-Meier method, data being measured 12 months after the completion of FCR treatment (to classify patients into MRD group A or B). Events relevant for the end point event-free survival were clinical progression, disease recurrence or death from any cause, transformation of any kind (one Richter's syndrome, one secondary acute myeloid leukemia due to treatment). Data were analyzed as of September 2009.
Results
Patients and clinical follow-up
Patient demographics are described in Table 1 . FCR yielded CR þ nodPR rate as high as 80%, with 10% CRi and 10% PRd rate (no stable disease or progressive patient). Response rate was correlated with stage C but not with other clinical or biological parameters. At 3 months after the last FCR course (EOT), fourcolor flow cytometry peripheral blood MRD level o10 4 was obtained in 16 of 30 (53.3%) patients. During follow-up (ranging from 12 to 46 months with a median of 30 months), 8 disease progressions occurred (disease-free survival (DFS) for the entire cohort was 67% at 26 months). In all cases, increase in MRD 410
À2 was detected at 3-6 months before clinical relapse. On molecular progression, three patients died (one from Richter's syndrome, two from severe sepsis), one needed re-treatment and four remained treatment-free (owing to Binet stage A disease, with discrete hyperlymphocytosis and palpable lymph nodes). Collectively, these results suggest that in the first year post-FCR, an MRD increase 41% of total leukocytes predicts clinical relapse. Immune cell recovery and MRD follow-up post-FCR L Ysebaert et al
Flow cytometry follow-up
MRD was assessed every 6 months for at least 1 year after FCR completion. At 1 year, 30 of 30 patients were informative. From EOT, different MRD profiles were observed, but we chose to classify patients according to the MRD outcome after 1 year into two groups ( Figure 1a ). Group A patients had MRD levels below 1% of total leukocytes (n ¼ 18 of 30), and group B patients had progressive MRD levels 41% of total leukocytes (n ¼ 12 of 30) at 12-month (M12) evaluation. Interestingly, two patients in group A showed progressive decrease in MRD levels (without receiving any treatment). From M12, group B had significantly shorter DFS (18 months vs not reached in group A, log-rank Po0.01) (Figure 1b) . Group A and group B showed no significant differences for Binet stage, del11q, IgVH mutational status and CD38 expression (data not shown). However, undetectable MRD at EOT evaluation was predictive of a favorable molecular outcome over the first year after treatment (P ¼ 0.014) (Figure 1c ). These data indicate that patients with MRD levels remaining o1% of leukocytes did not experience clinical relapse, suggesting the occurrence of some immunomodulating events.
Immune subset recovery after FCR NK, monocytes, T CD4/CD8 and Tgd lymphocyte counts reconstitution are presented in Figure 2a . FCR induced a sharp and prolonged decrease in values for all lymphoid subpopulations, compared with the pre-FCR period. The median time to reach CD4 þ 4200 cells per ml was 6 months (but up to 24 months to reach 400 cells per ml), and the median CD8 þ levels reached the normal range after 12 months. T Vg9d2 lymphocytes showed profound and sustained depletion.
NK cells were relatively preserved, although they remained below the normal range ( Figure 2) . From EOT to M12, NK cells accounted for up to 32% of PBL, endowed with potential ADCC, because they express CD16 (Figure 2b ). Normal B cells (Figure 2c , calculated from MRD dot plot analyses) rapidly increased, to reach almost normal ranges (2-3% of leukocytes, instead of 3-6%) in the first year post-immunochemotherapy. The only patient with decreased B cell numbers is the patient who required second-line treatment at 15 months after FCR. Altogether, these findings showed that Tgd and CD4 þ T cells were much more sensitive to FCR than NK cells.
NK function recovery
As NK cells are believed to be important immune effectors for both disease control and defenses against pathogens, we investigated whether FCR could have influenced intrinsic NK function. For this reason, we measured at different times the natural PBL lysis capacity against MEC-2, a CLL-derived cell line, at the low effector/target ratio of 0.4:1. As shown in Figure 3a , we found that resting PBL from healthy donors showed a modest activity against MEC-2 (4.7 ± 3.5%), the latter being dramatically boosted when PBLs were stimulated by IL-2 (LAK activity) (24.8 ± 14%). As shown in Figure 3a , when tested at the overt phase of the disease, resting B-CLL PBL showed similar cytotoxicity against MEC-2, compared with healthy donors (1.4±1.1%). However, when IL-2 was used, LAK activity was much lower, compared with normal healthy donors (6.5±4.3%, P ¼ 0.004), suggesting that LAK function was indeed depressed in B-CLL samples (Figure 3a) . Moreover, as depicted in Figure 3b , LAK activity progressively increased and was totally restored at M12 compared with EOT in eight Immune cell recovery and MRD follow-up post-FCR L Ysebaert et al PMN counts, as well as for NK and LAK activities against MEC-2, measured at EOT, M6 and M12. As illustrated in Figure 4 , group A showed significantly lower CD4 þ counts at EOT (median ¼ 133 vs 225 per ml, n ¼ 26, P ¼ 0.02), and a slow CD4 þ T-cell recovery during the first year post-FCR (median at M12: 233 vs 419 per ml, n ¼ 25, P ¼ 0.02). We found no correlation with the other parameters at any other time point, including NK or LAK function (data not shown). Best CD4 count cutoffs to predict DFS were o150 per ml at EOT (DFS 30 vs 16 months, P ¼ 0.008), and o300 per ml at M12 (DFS from M12 post-FCR: 19 vs 7 months, Po0.01).
Correlation between MRD and immune recovery
PBL cellular cytotoxicity against autologous B-CLL cells after FCR
On the basis of the above findings, which indicated that the NK/LAK function was improved during the first year post-FCR, we speculated that PBL from CLL patients treated with FCR could exert potent RTX-mediated ADCC against autologous leukemic cells. From unpaired analyses, we first compared RTX-ADCC ±IL-2 from CLL patients before and 12 months after FCR, but detected no statistical difference (mean RTX-ADCC þ IL-2 was 8.1±4% at baseline vs 18±12% at M12, n ¼ 6). We then focused on these six patients at M12 (three from each MRD group, A and B). Against autologous B-CLL cells, group A patients show statistically different RTX-ADCC (28.8±7% vs 8.1 ± 2.8% in group B, P ¼ 0.03, Figure 5 ). These results suggest that although the LAK function was dramatically improved by FCR therapy, NK remained ineffective against the leukemic clone, unless being used in association with RTX, which may redirect intrinsically efficient NK cells toward their targets, or trigger secondary signals resulting in boosting their cytolytic function.
Discussion
Although FCR has become one of the major standards for B-CLL, scarce information is available on long-term immune reconstitution after therapy. Recently, concerns about FCR-induced immunosuppression were raised about the relatively high rate of opportunistic infection during the post-FCR period. 1 We also Immune cell recovery and MRD follow-up post-FCR L Ysebaert et al addressed the kinetics of MRD levels after FCR, and its relevance for the prediction of clinical relapse. Correlative studies between both recovery data (immune cells and MRD) point toward a putative role of the immune system in the control of CLL post-FCR. Unsurprisingly, we have found that FCR induced a severe and prolonged depletion of all T-cell subsets. Previous studies have largely documented the sensitivity of CD4 and CD8 T cells to fludarabine. 13, 14 However, the impact of the drug on Tgd subset has not so far been reported. These cells were found to be even more sensitive than Tab cells. The extent to which severe Tgd depletion contributes to FCR-associated opportunistic infection remains to be determined. This question is of interest because of the introduction of phosphoantigen-based preparations able to expand in vivo Tgd cell population. 9 Interestingly, NK cells were relatively preserved. This observation is in sharp contrast with alemtuzumab therapy, which was found to be harmful toward NK cells. 15 PBLs derived from B-CLL patients have much lower cellular cytotoxic capacity, compared with those from healthy donors. As NK cells support most, if not all, PBMC natural cytotoxicity, 16 this observation suggests that, before treatment, NK basal function is profoundly altered in B-CLL. Decrease in NK-mediated B-CLL lysis has been largely described. However, it remains unclear whether CLL cell natural resistance or decreased function of B-CLL patient NK cells has the more important role. Our study shows that NK activity in autologous RTX-ADCC improved during the post-FCR period in some patients (who could benefit from RTX maintenance treatment), but remained very low in others, suggesting that these latter patients are endowed with highly NK-resistant CLL cells.
MRD eradication during and post-FCR is predictive of better outcome in the CLL8 trial. Extensive data on MRD monitoring post-FCR are lacking. Such data collected after bone marrow grafting procedures indicated MRD increase as a good predictive marker for clinical relapse. [17] [18] [19] In our cohort of 30 patients, 8 out of 12 patients from group B (MRD 41% at M12) suffered a relapse, with increasing levels of MRD 41% being always detected 3-6 months before clinical relapse. MRD monitoring at 12 months after FCR identified patients with a high relapse risk, who could benefit from investigational treatments aiming to prevent overt relapse. The choice of MRD threshold is nonetheless questionable. Using a 0.05% threshold (as proposed recently in the post-allograft setting 19 ), four patients from group A would fall into group B, none with overt clinical relapse (despite 424 months of follow-up). Thus, the size of our cohort may limit the significance of a 1% threshold: the main message is clearly that MRD monitoring should be implemented in the follow-up of FCR patients because of its relevance in predicting clinical evolution of the disease. Another interesting result suggests a negative impact of CD4 þ cell recovery on molecular disease control. This observation is in agreement with another study presented very recently. 20 The significance of these observations remains unclear. They may simply reflect a surrogate biomarker of FCR efficacy against lymphocytes. Characterization of these CD4 þ cells was beyond the scope of this study. It seems unlikely that these cells are CD4
þ Treg, which could have thus facilitated tumor cell escape. Indeed, Treg cells are exquisitely sensitive to fludarabine and indeed efficiently depleted by this drug. 14 Alternatively, it is possible that these CD4 þ cells correspond to an expansion of cytokine-producing cells, which may exert a direct helper function toward tumor cells, as for example CD4 þ CD154 þ cells, a subset that was found to facilitate proliferation, survival and immuno-escape of CLL cells. 21 CD4 monitoring cannot be considered as a surrogate marker for MRD evolution of course, but future strategies aiming at modulating CD4 þ subsets (Tregs, Th17) may prove of interest in CLL. In a view of immunomodulation strategies early post-FCR, we present data indicating that natural effectors, presumably NK cells, exert in the presence of RTX cellular cytotoxicity against autologous leukemic cells. Interestingly, such RTX-mediated ADCC of patient PBL improved during the post-FCR period and reached levels comparable to that of normal healthy donors (data not shown). We believe that ADCC increase is due to enhanced NK function during the same period of time. This finding is important to consider because ADCC is the major mechanism by which RTX exerts its anti-leukemic effect. This consideration, combined with the observation that MRD control during the 1-year post-FCR period seems to be critical for future clinical outcome, argues for the use of RTX as maintenance or consolidation therapy during the first year following FCR completion. RTX-based maintenance therapy is currently being tested in the setting of FCR-treated B-CLL (French collaborative CLL2007-SA phase III trial). Whether these studies will confirm our hypothesis is still unknown. Our study also suggests that this strategy should benefit from co-administration of NK-stimulating cytokines such as IL-2, 22 IL-15 23 or IL-21 24 or drugs susceptible to enhance NK function, such as Lenalidomide. 25 To conclude, our study shows that FCR therapy induces a severe and prolonged T-cell depletion; however, NK cells are less affected and NK function even increases 1 year after treatment, with potential autologous RTX-ADCC restoration. We also provide evidence that MRD monitoring the first year post-FCR is of clinical importance to predict relapses and manage preemptive therapeutic strategies. Altogether, these results support the use of anti-CD20-based maintenance therapy in B-CLL to maintain low levels of MRD, prolong PFS and perhaps improve survival.
